In scRNA-seq, the tSNE plots and the expression dot plots showed cellular components in the allografts classified by the indicated TME markers: cancer cell (J558-allograft), monocyte, CD8 + T cell, CD4 + T cell, NK cell, endothelial cell, fibroblast, and undefined (Fig. 6c–f and Fig. S14a–c), demonstrating that TAK-931 treatment prominently promoted tumor infiltration of both adaptive (CD8+ T cell and CD4+ T cell) and innate (NK cells and monocytes) immune cells in the allografts. The gene discussed is CD8A; the disease is neoplasm.